SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting
 

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

More...